NexMed, Inc. (Nasdaq: NEXM), a developer of original transcutaneous products supported on its copyrighted NexACT® take conveying technology, declared fleshliht the New Drug Application (NDA) filed by the Company for its expansive pathology (ED) product, a topically practical alprostadil cream, was acknowledged for analyse by the U.S. Food and Drug Administration (FDA).
Leave a Comment
